Trial Profile
A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 Feb 2020 Status changed from active, no longer recruiting to discontinued, results presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium
- 29 Feb 2020 Interim results were presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium
- 20 Feb 2020 Primary endpoint has not been met. (Percent Disease Control Rate), according to results published in the Investigational New Drugs